千金药业：子公司千金湘江药业获得盐酸鲁拉西酮片药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, which is used for the treatment of schizophrenia, enhancing the company's product pipeline and supporting sustainable development [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1] - The approval of Lurasidone Hydrochloride Tablets signifies that the product has passed the consistency evaluation, which is a positive development for the company's product offerings [1] Industry Summary - Other companies that have received the drug registration certificate for Lurasidone Hydrochloride Tablets include Jiangsu Hengrui Medicine Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Haizheng Pharmaceutical Co., Ltd. [1] - The production and sales of the drug are subject to significant uncertainties due to factors such as national policies and market environment changes [1]